Blood cancer (AML leukaemia)
A study to compare two types of chemotherapy that is 3 plus 7 & AZA plus VEN for the treatment of a blood cancer called Acute Myeloid Leukemia
Who can joinAdults
Age18+ years
Kind of studyObservational: no new treatment
What it testsWatches and records only
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
Tata Memorial HospitalMumbaiDirections ↗
Registry summary (technical)
A single centre prospective observational study to compare the outcomes & toxicities of Azacitidine plus Venetoclax (AZA plus VEN) with 3 plus 7 induction chemotherapy (IC) with Cytarabine and Daunorubicin in patients with Acute Myeloid Leukemia (AML)
Sponsor: Dr Manju Sengar
CTRI/2023/06/053981 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 30 Mar 2026 · read by us 5 Nov 2026